Co-Delivery of Itraconazole and Docetaxel by Core/Shell Lipid Nanocells for Systemic Antiangiogenesis and Tumor Growth Inhibition

• DOI: 10.1166/jbn.2017.2428
• Publication Date: 2018-09-28T03:23:52Z
• Authors: Chukwunweike I. O...; Ahmed S. Eltahan; Tingbin Zhang; Jing Chen; Yingze Wang; Meng-Qi Xu; Lu Liu; An-Qi Yang; Weisheng Guo; Xing-Jie Liang
• Keywords: Matrigel

The combination of antiangiogenesis with chemotherapy has become a promising multi-modal combinational therapy for solid tumor. However, hypoxia-mediated resistance and the subsequent treatment failure associated have limited maximization this approach. It remains major challenge to balance effect angiogenesis accumulation cytotoxic drug within tumor microenvironment. In study, we report nanotechnology based delivery solution that would improve both antiangiogenic activity efficacy loaded drugs. We designed core-shell 'lipid nanocells' systems (denoted as DTX/ITZ-LNCs), which entrapped itraconazole (ITZ) in outside liposomal shell encapsulated anticancer docetaxel (DTX) inner hydrophobic PLGA core. vitro evaluations showed dual DTX/ITZ-LNCs retained DTX against sensitive multidrug resistant breast cancer cell line MCF-7. also effectively inhibited vascular endothelial growth factor (VEGF) induced migratory invasive actions HUVECs neovascularization subcutaneously implanted matrigel plugs. MCF-7 xenograft model was by systemic administration DTX/ITZ-LNCs. Taken together, these results provided platform can optimize combinatory effects agent conventional chemotherapeutic agent.